![PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate (PDC*lung01) targeting non-small cell lung cancer](https://ala.associates/wp-content/uploads/2022/04/22-janvier-2020-Mr.jpg)
![PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate (PDC*lung01) targeting non-small cell lung cancer](https://ala.associates/wp-content/uploads/2022/04/22-janvier-2020-Mr.jpg)
![Advanced BioDesign raises additional €9 million from Xerys Funds](https://ala.associates/wp-content/uploads/2022/04/25-fevrier-2020-MR.jpg)
Advanced BioDesign raises additional €9 million from Xerys Funds
![Oncodesign and Servier reach a key first milestone in their strategic partnership](https://ala.associates/wp-content/uploads/2022/04/17-fevrier-2020.png)
Oncodesign and Servier reach a key first milestone in their strategic partnership
![Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking](https://ala.associates/wp-content/uploads/2022/04/13-janvier-2020.png)
Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking
![Yposkesi’s clinical batches of the G1XCGD lentiviral vector used in rare immune system disease study](https://ala.associates/wp-content/uploads/2022/04/29-janvier-2020.jpg)
Yposkesi’s clinical batches of the G1XCGD lentiviral vector used in rare immune system disease study
![Cynbiose receives €1.9 million ($2.1M) to launch CYNBIOME, preclinical excellence network on microbiome and infectious diseases](https://ala.associates/wp-content/uploads/2022/04/28-Janvier-2020.jpeg)
Cynbiose receives €1.9 million ($2.1M) to launch CYNBIOME, preclinical excellence network on microbiome and infectious diseases
![Nuvisan Pharma Services acquires Inamed GmbH](https://ala.associates/wp-content/uploads/2022/04/23-janvier-2020.jpg)
Nuvisan Pharma Services acquires Inamed GmbH
![PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate (PDC*lung01) targeting non-small cell lung cancer](https://ala.associates/wp-content/uploads/2022/04/22-janvier-2020-Mr.jpg)
PDC*line Pharma raises €20 million in Series B financing round
![Advanced BioDesign joins ENHPATHY corsortium to increase its knowledge in genetic alterations in hematologic cancers](https://ala.associates/wp-content/uploads/2022/04/21-janvier-2020-ENHPATHY.png)
Advanced BioDesign joins ENHPATHY corsortium to increase its knowledge in genetic alterations in hematologic cancers
![Biotech start-up Seekyo raises €800k with leverage from French Tech Seed Fund](https://ala.associates/wp-content/uploads/2022/04/20-janvier-2020.jpg)